Citadel Advisors
MIRM icon

Citadel Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Citadel Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,052,048
Closed -$106M – 14417
2026
Q1 		$97.2M Buy
1,052,048
+211,828
+25% +$19.9M 0.02% 826
2025
Q4 		$66.4M Sell
840,220
-200,324
-19% -$14.4M 0.01% 1167
2025
Q3 		$76.3M Sell
1,040,544
-365,808
-26% -$23.3M 0.01% 1038
2025
Q2 		$71.6M Sell
1,406,352
-39,643
-3% -$1.77M 0.01% 982
2025
Q1 		$65.1M Sell
1,445,995
-65,188
-4% -$3.07M 0.01% 949
2024
Q4 		$62.5M Buy
1,511,183
+119,774
+9% +$4.99M 0.01% 1085
2024
Q3 		$54.3M Sell
1,391,409
-194,215
-12% -$7.75M 0.01% 1140
2024
Q2 		$54.2M Buy
1,585,624
+193,118
+14% +$5.06M 0.01% 1087
2024
Q1 		$35M Sell
1,392,506
-50,306
-3% -$1.38M 0.01% 1508
2023
Q4 		$42.6M Sell
1,442,812
-274,445
-16% -$8.31M 0.01% 1305
2023
Q3 		$53.7M Buy
1,717,257
+287,412
+20% +$7.87M 0.01% 1015
2023
Q2 		$37M Buy
1,429,845
+60,500
+4% +$1.61M 0.01% 1297
2023
Q1 		$32.9M Sell
1,369,345
-39,214
-3% -$894K 0.01% 1450
2022
Q4 		$27.5M Buy
1,408,559
+483,382
+52% +$9.55M 0.01% 1633
2022
Q3 		$19.4M Buy
925,177
+495,330
+115% +$11.9M ﹤0.01% 1901
2022
Q2 		$8.37M Buy
429,847
+96,819
+29% +$2.28M ﹤0.01% 2917
2022
Q1 		$7.33M Buy
333,028
+206,602
+163% +$4.21M ﹤0.01% 3466
2021
Q4 		$2.02M Buy
126,426
+39,948
+46% +$621K ﹤0.01% 6218
2021
Q3 		$1.72M Buy
+86,478
New +$1.41M ﹤0.01% 6743
2021
Q1 		– Sell
-15,437
Closed -$269K – 13525
2020
Q4 		$269K Sell
15,437
-11,442
-43% -$225K ﹤0.01% 9253
2020
Q3 		$518K Buy
26,879
+13,742
+105% +$295K ﹤0.01% 7245
2020
Q2 		$256K Buy
+13,137
New +$220K ﹤0.01% 8171

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's MIRM Position: Q2 2026 in Review

Citadel Advisors sold out of Mirum Pharmaceuticals (MIRM) in Q2 2026, closing a stake of 1,052,048 shares — an estimated $106M sold.

Citadel Advisors first reported a position in MIRM in Q2 2020 and held it in 22 quarters. The position peaked at $97.2M in Q1 2026. 328 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Citadel Advisors reported no remaining Mirum Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,052,048 Mirum Pharmaceuticals shares in Q2 2026, an estimated $106M.
  • Citadel Advisors first reported a position in Mirum Pharmaceuticals in Q2 2020 and held it in 22 quarters.
  • Citadel Advisors's Mirum Pharmaceuticals position peaked at $97.2M in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.